Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients

June 11, 2026 4:01 PM

Ascendis Pharma A/S (NASDAQ: ASND) announced results from a 5-year Phase 2 trial showing sustained efficacy and safety of TransCon ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found